Catalyst Pharmaceuticals, Inc.
CPRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. Valued at $3.85B, CPRX is a mid-cap name in its sector. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.
Market Cap
$3.85B
Beta
0.74
P/E (TTM)
18.20
P/E (Fwd)
9.90
EPS (TTM)
$1.73
EPS (Fwd)
$3.18
ROE
24.5%
ROA
16.3%
Cash
$755.9M
Total Debt
$2.7M
Free CF
$171.8M
52W Change
48.7%
Annual Financials
Cash vs Debt
Catalyst Pharmaceuticals, Inc. holds $755.9M in cash against $2.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $171.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 24.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 16.3% further supports the picture of efficient asset utilization. Revenue has grown from $214.2M (2022) to $589.0M (2025), reflecting a 175% increase over the period.
With cash comfortably exceeding debt, CPRX has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CPRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.